A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Pharmacodynamics of SHR-2010 by Intravenously/Subcutaneously in Healthy Subject

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

61 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-30

Study Completion Date

2023-03-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is being conducted to Evaluate the Safety, Tolerability and Pharmacokinetics pharmacodynamics of SHR-2010 by intravenously/subcutaneously in Healthy Subject.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase I Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Injection of SHR-2173 in Healthy Subjects

NCT06995001

Healthy Volunteers

COMPLETED PHASE1

A Phase I Study of SHR -2001 in Healthy Subjects

NCT05942612

Healthy

COMPLETED PHASE1

Safety, Tolerability and PK/PD of SHR1459 in Healthy Volunteers

NCT03668509

Healthy Volunteers

UNKNOWN PHASE1

A Phase I Clinical Study on SHR6390 in Healthy Chinese Volunteers

NCT05354336

Healthy Volunteers

COMPLETED PHASE1

The Safety, Tolerability, Pharmacokinetics(PK) of SR419 in Healthy Volunteers

NCT04021563

Healthy Volunteers

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

IgA Nephropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

SHR-2010 injection compared with placebo

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment for intravenously/subcutaneously

Treatment for intravenously: 6 dose groups； Treatment for subcutaneously: 3 dose groups.

Group Type EXPERIMENTAL

SHR-2010 injection

Intervention Type DRUG

Treatment for intravenously: 6 subjects for SR-2010 injection. Treatment for subcutaneously: 8 subjects for SR-2010 injection.

Placebo for intravenously/subcutaneously

Treatment for intravenously: 6 dose groups； Treatment for subcutaneously: 3 dose groups.

Group Type PLACEBO_COMPARATOR

SHR-2010 injection placebo

Intervention Type DRUG

Treatment for intravenously: 2 subjects for placebo. Treatment for subcutaneously: 2 subjects for placebo.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SHR-2010 injection

Treatment for intravenously: 6 subjects for SR-2010 injection. Treatment for subcutaneously: 8 subjects for SR-2010 injection.

Intervention Type DRUG

SHR-2010 injection placebo

Treatment for intravenously: 2 subjects for placebo. Treatment for subcutaneously: 2 subjects for placebo.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Able and willing to provide a written informed consent.
2. Male or non-pregnant, non-lactating female ages 18 to 55 years old.
3. Weight ≥ 45 kg, and body mass index (BMI) must range from 18 to 28 kg/m2 .
4. Healthy subjects as determined by absence of clinically significant abnormalities on medical history, physical examination, vital signs, 12-lead ECG and clinical laboratory tests performed at screening or baseline period.
5. Subjects must be willing to use a highly effective method of contraception as deemed appropriate by the investigator throughout the study and for at least 3 months after the last study drug administration.

Exclusion Criteria

1. Evidence or history of serious cardiovascular, hepatic, renal, gastrointestinal, psychiatric, neurological, haematological, or metabolic diseases within 5 years.
2. Subjects with tuberculosis diagnosed by Interferon Gamma Release Assays (IGRA) or chest X-ray.
3. Subjects had any surgery within the past 6 months before screening or planned to undergo surgery during the study period.
4. Estimated Glomerular Filtration Rate（eGFR）\<90 mL/min/1.73m2.
5. Positive for hepatitis (including hepatitis B and C), HIV or syphilis at screening.
6. Systolic blood pressure (SBP) \> 140 mm Hg or \< 90 mm Hg, or diastolic blood pressure (DBP) \> 90 mm Hg or \< 60 mm Hg and has been considered clinically significant.
7. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) or gamma-glutamyl transferase (GGT) ≥2.0 x ULN, or total bilirubin ≥1.5 x ULN.
8. Clinically significant abnormal 12-lead ECG at screening (male with QTcF \> 450 ms or female with QTcF \> 470 ms).
9. Female subjects who had unprotected sexual behaviour within 14 days before screening.
10. Positive for alcohol breath test at screening or baseline period.
11. Positive urinary drug test at screening or baseline period.
12. Blood collection is difficult or cannot tolerate venipuncture blood collection.
13. Allergic to any ingredient or component in the study drug.
14. Subjects who have taken any prescription drugs, over-the-counter drugs, or Chinese herbal medicine within 14 days prior to using the study drug.
15. Subjects who smoked more than 5 cigarettes daily in the 1 month before screening.
16. History of regular alcohol consumption exceeding 3 units/day for women or 5 units/day for men, more than twice per week (1 unit = 150 ml of beer or 50 ml of wine or 17 ml of alcoholic spirits) within 3 months before screening.
17. Participated in any other clinical trials of any drug or medical device within 3 months before screening.
18. Donated blood or blood products or had substantial loss of blood (more than 400 mL) within 1 month before screening, or received any blood or blood products within 2 months prior to screening.
19. Subjects who received live (attenuated) vaccine within 1 month prior to screening or consider getting a vaccination during the study.
20. The employee of investigator or study centre, with direct involvement in the proposed study.
21. The investigators determined that other conditions were inappropriate for participation in this clinical trial.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes